Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis

Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub‐phenotypes.

[1]  M. D’Amato,et al.  Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression , 2021, Journal of asthma and allergy.

[2]  E. Nettis,et al.  Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: Data from a real-life cohort. , 2020, Pulmonary pharmacology & therapeutics.

[3]  E. V. van Roon,et al.  Prediction of response to biological treatment with monoclonal antibodies in severe asthma. , 2020, Biochemical pharmacology.

[4]  G. Canonica,et al.  Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma , 2020, Allergy.

[5]  G. Canonica,et al.  The evolving algorithm of biological selection in severe asthma , 2020, Allergy.

[6]  Chuntao Liu,et al.  Dupilumab in patients with uncontrolled asthma: type 2 biomarkers might be predictors of therapeutic efficacy , 2020, The Journal of asthma : official journal of the Association for the Care of Asthma.

[7]  S. Jang,et al.  Association Between Asthma and Depression: A National Cohort Study. , 2019, The journal of allergy and clinical immunology. In practice.

[8]  P. Howarth,et al.  Randomised controlled trials in severe asthma: selection by phenotype or stereotype , 2018, European Respiratory Journal.

[9]  E. Bleecker,et al.  Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma , 2018, European Respiratory Journal.

[10]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[11]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[12]  E. Brown,et al.  The relationship between asthma and depression in a community-based sample , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

[13]  E. Bel,et al.  New Anti‐Eosinophil Drugs for Asthma and COPD: Targeting the Trait! , 2017, Chest.

[14]  C. Powell,et al.  Anti-IL5 therapies for asthma. , 2017, The Cochrane database of systematic reviews.

[15]  C. Jenkins,et al.  Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[16]  E. Heffler,et al.  Point-of-care blood eosinophil count in a severe asthma clinic setting. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[18]  F. Albers,et al.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.

[19]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[20]  A. Buist,et al.  Complementing the randomized controlled trial evidence base. Evolution not revolution. , 2014, Annals of the American Thoracic Society.

[21]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[22]  V. Lund,et al.  Psychometric validity of the 22‐item Sinonasal Outcome Test , 2009, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[23]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[24]  J Zhang,et al.  What are minimal important changes for asthma measures in a clinical trial? , 1999, The European respiratory journal.

[25]  G. Guyatt,et al.  Development and validation of the Mini Asthma Quality of Life Questionnaire. , 1999, The European respiratory journal.

[26]  E. Bleecker,et al.  Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. , 2018, The Lancet. Respiratory medicine.

[27]  Philip Marcus,et al.  Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.

[28]  E. Bel.  Clinical phenotypes of asthma. , 2004, Current opinion in pulmonary medicine.

[29]  J. Butcher,et al.  4.14 – Objective Personality Assessment with Adults , 1998 .